NX-2127
Product Specifications
CAS Number
2416131-46-7
Target
BTK, PROTACs, IKZF
Related Pathways
PROTAC, Angiogenesis, Immunology/Inflammation, Tyrosine Kinase/Adaptors
Purity
0.9907
Bioactivity
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells.
Smiles
O=C1C=2C(C(=O)N1C3C(=O)NC(=O)CC3)=CC=C(C2)N4C[C@H](CN5CCC(CC5)C6=CC=C(NC=7C(C(N)=O)=NC=C(N7)N8CCCCC8)C=C6)CC4
Molecular Formula
C39H45N9O5
Molecular Weight
719.83
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
037563-PE 200 µL
KLHL9, ID (KLHL9, KIAA1354, Kelch-like protein 9) (PE) discontinued
Sign In for Pricing
View Details 
MBS1029068-01 0.02 mg (E-Coli)
Recombinant Clostridium botulinum V-type ATP synthase subunit D (atpD)
Sign In for Pricing
View Details MBS1029068-02 0.1 mg (E-Coli)
Recombinant Clostridium botulinum V-type ATP synthase subunit D (atpD)
Sign In for Pricing
View Details